Google Scholar
The investigators' aim in this latest FIELD report was to assess whether long-term lipid-lowering therapy with fenofibrate could reduce retinopathy progression in a
These findings suggest that fenofibrate may be an effective strategy for reducing the progression of diabetic retinopathy, thus reducing the large and growing
Studies have investigated fenofibrate use as a protective measure with conflicting results, and fenofibrate is not typically considered by ophthalmologists in the management of DR currently
The subgroup analyses showed that patients with baseline retinopathy of level 2 to 4 (as per the seventeen step scale in the study) had a reduced rate of the primary outcome from 10
Our aim was to assess whether long-term lipid-lowering therapy with fenofibrate could reduce the progression of retinopathy and the need for laser treatment in patients with type 2 diabetes mellitus
Several case series and a controlled prospective study suggest that pregnancy in patients with type 1 diabetes may aggravate retinopathy and threaten
Of the 9795 participants randomised into the FIELD study, 4895 were assigned to receive fenofibrate and 4900 were assigned to receive matching placebo
Oxidative stress and neuroinflammation contribute significantly to the development and progression of diabetic retinopathy
Diabetic retinopathy (DR) is common, with estimated prevalences of 25% (type 2 diabetes [T2D]) and 77% (type 1 diabetes [T1D])
use of fenofibrate for this indication
Background and Objectives: Fenofibrate, a PPAR-α agonist, has been demonstrated to reduce the progression of diabetic retinopathy (DR) and the need for laser treatment in a FIELD (Fenofibrate Intervention and Event Lowering in Diabetes) study
Despite the benefits of fenofibrate, we don’t see recommendations for
In the present study, we evaluate the effect and mechanism of fenofibrate on regulating the oxidative